In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Sarepta Therapeutics Inc (NASDAQ: SRPT) closed at $126.00 down -1.39% from its previous closing price of $127.78. In other words, the price has decreased by -$1.39 from its previous closing price. On the day, 0.65 million shares were traded. SRPT stock price reached its highest trading level at $128.19 during the session, while it also had its lowest trading level at $125.92.
Ratios:
For a deeper understanding of Sarepta Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.19 and its Current Ratio is at 3.90. In the meantime, Its Debt-to-Equity ratio is 1.27 whereas as Long-Term Debt/Eq ratio is at 1.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on October 21, 2024, initiated with a Buy rating and assigned the stock a target price of $165.
RBC Capital Mkts Upgraded its Sector Perform to Outperform on July 29, 2024, while the target price for the stock was maintained at $182.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 30 ’24 when Estepan Ian Michael sold 5,985 shares for $137.36 per share. The transaction valued at 822,100 led to the insider holds 33,946 shares of the business.
Estepan Ian Michael bought 5,985 shares of SRPT for $822,130 on Aug 30 ’24. On Aug 16 ’24, another insider, Chambers Michael Andrew, who serves as the Director of the company, bought 37,038 shares for $133.80 each. As a result, the insider paid 4,955,728 and bolstered with 284,034 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 12177799168 and an Enterprise Value of 11942727680. As of this moment, Sarepta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 311.50, and their Forward P/E ratio for the next fiscal year is 11.23. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.98 while its Price-to-Book (P/B) ratio in mrq is 11.15. Its current Enterprise Value per Revenue stands at 7.935 whereas that against EBITDA is 153.604.
Stock Price History:
Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $55.25. The 50-Day Moving Average of the stock is -1.47%, while the 200-Day Moving Average is calculated to be -3.45%.
Shares Statistics:
For the past three months, SRPT has traded an average of 909.58K shares per day and 698400 over the past ten days. A total of 93.73M shares are outstanding, with a floating share count of 89.52M. Insiders hold about 6.13% of the company’s shares, while institutions hold 92.52% stake in the company. Shares short for SRPT as of 1728950400 were 5657186 with a Short Ratio of 6.22, compared to 1726185600 on 6146823. Therefore, it implies a Short% of Shares Outstanding of 5657186 and a Short% of Float of 6.2.
